Efgartigimod PH20 SC for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
argenx· ARGX-113-1803
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT04280718 on ClinicalTrials.gov →Study type
interventional
Design
Open-label, single-group, exte…
Target enrollment
229
Est. completion
2027-04-30
Investor scorecard
Probability of success
high
Timeline to catalyst
The trial is expected to complete in April 2027. Interim data may be presented at medical conferences in 2024-2025, which could provide early signals on safety and efficacy.
Potential stock impact
SignificantThe drug has already shown efficacy in a phase 2 trial, and this extension study is primarily for long-term safety and durability. Since the mechanism is well-established and the drug is already approved for another indication, the risk of failure is relatively low. However, long-term safety issues could arise, and the open-label design without a control group limits the ability to confirm efficacy, but the primary endpoint is safety, which is likely to be acceptable.
What is being tested?
This trial is testing a drug called efgartigimod, given as a shot under the skin, to see if it is safe and works over a long time for people with a nerve disease called CIDP. CIDP is a rare condition where the body's immune system attacks the protective covering of nerves, causing weakness and numbness. The drug works by blocking a protein that helps the immune system attack, so it might reduce the damage. This is an extension study, meaning people who finished a previous trial can continue getting the drug to see if it keeps working and stays safe.
How does the trial work?
This is an open-label study, so everyone knows they are getting the drug. There is no placebo. People who completed the earlier trial (ARGX-113-1802) can join. They will receive efgartigimod injections regularly for up to about 6 years. Doctors will check them often for side effects and measure how well they are doing using tests like the INCAT score (which rates disability), muscle strength, and grip strength. The goal is to see if the drug continues to help and if any long-term problems pop up.
What does success look like?
Success means that the drug remains safe over the long term, with no new or serious side effects that outweigh the benefits. It also means that the improvements in disability, muscle strength, and daily function seen in the earlier trial are maintained or even improved. For example, patients should not get worse on the INCAT score, and their muscle strength should stay stable or get better. If the drug fails, we might see a return of symptoms or an increase in side effects.
What it means for investors
For investors, this trial is about long-term safety and durability of effect. If the drug is safe and effective over years, it could support regulatory approval and market expansion. argenx already has approval for efgartigimod in myasthenia gravis, and a positive result here could open up a new indication, increasing the addressable market. If safety issues emerge or efficacy wanes, it could hurt the stock. The trial is expected to complete in 2027, so catalysts are years away, but interim data could provide signals. Investors should watch for any early discontinuations or serious adverse events.
Trial endpoints
Primary endpoints
Secondary endpoints
Competitive landscape
CIDP is a rare disease affecting about 1-2 per 100,000 people, so the patient population is small. However, the current treatments (IVIG, steroids, plasmapheresis) are not always effective and can be burdensome. Efgartigimod offers a novel mechanism that could provide a more targeted and convenient option. The market for CIDP treatments is estimated to be around $1 billion globally, and a successful drug could capture a significant share if it shows better efficacy or safety.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Privigen (IVIG) | CSL Behring | Phase 1 | Standard of care, but requires frequent intravenous infusions and can have side effects. |
| Hizentra (SCIG) | CSL Behring | Phase 1 | Subcutaneous immunoglobulin, also standard of care, but still requires regular injections. |
| Rituximab | Roche | Phase 1 | B-cell depleting antibody, being tested in CIDP, but has different mechanism and safety profile. |
Historical context
Prior trial results
The preceding trial (ARGX-113-1802) was a phase 2 study that showed efgartigimod was effective in reducing relapse risk in CIDP patients. It met its primary endpoint, and the results were published in 2021. The drug was generally well-tolerated.
Regulatory history
Efgartigimod has received FDA approval for generalized myasthenia gravis (gMG) under the brand name Vyvgart. It has also been granted Orphan Drug Designation for CIDP by the FDA. No breakthrough therapy designation for CIDP yet, but the positive phase 2 data may support that.
Similar drug precedents
Other FcRn inhibitors like rozanolixizumab (UCB) and nipocalimab (J&J) are being developed for similar autoimmune diseases. In CIDP, IVIG and subcutaneous immunoglobulin are the mainstays, but they require frequent dosing. Efgartigimod's subcutaneous formulation could offer more convenience.